Ionis Pharmaceuti…
USUSDIonis Pharmaceuticals Inc (LSE:0JDI) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 3. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- ionis.com
- Investor relations
- ir.ionis.com/
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Headquarters
- CARLSBAD, United States
- Management
- Employees
- 1 480
- Listed since
- 29.01.2018 (LSE:0JDI)
- Shares outstanding
- Free float
- 164.82 M
- Market cap
- 7.42 B USD
- Insiders
- 0.61%
- Institutions
- 110.5%
- Industry (SIC)
- Pharmaceutical Preparations
- Legal form
- XTIQ
- ISIN
- US4622221004
- LEI
- 549300SI4ZGLG0BLUZ92
- P/E
- loss
- P/B
- 16.4
- FCF
- −561 M USD
- Debt
- 1.81 B USDnegative FCF — not covered
- Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
- NAV
Description
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| FMR, LLC | 14.82% | 24.63 M | 2026-06-30 |
| Capital World Investors | 13.04% | 21.67 M | 2026-06-30 |
| Blackrock Inc. | 6.44% | 10.7 M | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 5.12% | 8.5 M | 2026-07-31 |
| Vanguard Portfolio Manag… | 4.73% | 7.86 M | 2026-06-30 |
| Growth Fund of America | 4.61% | 7.67 M | 2026-06-30 |
| Wellington Management Gr… | 4.6% | 7.65 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.34% | 7.21 M | 2026-06-30 |
| Two Sigma Investments, L… | 3.76% | 6.25 M | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 3.74% | 6.21 M | 2026-07-31 |
| Royal Bank of Canada | 3.72% | 6.18 M | 2026-06-30 |
| SmallCap World Fund Inc | 3.17% | 5.26 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3% | 4.99 M | 2026-06-30 |
| New Economy Fund | 2.93% | 4.87 M | 2026-06-30 |
| State Street Corporation | 2.61% | 4.33 M | 2026-06-30 |
| T. Rowe Price Investment… | 2.38% | 3.96 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 3.6 M | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.44% | 2.39 M | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.25% | 2.08 M | 2026-06-30 |
| T. Rowe Price Mid-Cap Gr… | 1.2% | 2 M | 2026-06-30 |
| MONIA BRETT P (Chief Exe… | ≈0.15% | 245 571 | 2026-06-26 |
| BERTHELSEN SPENCER R (Di… | ≈0.1% | 161 303 | 2026-07-15 |
| HOUGEN ELIZABETH L (Chie… | ≈0.05% | 82 660 | 2026-03-17 |
| SCHNEIDER EUGENE (Office… | ≈0.05% | 77 114 | 2026-06-26 |
| BIRCHLER BRIAN (Officer) | ≈0.04% | 67 500 | 2026-04-16 |
| O'NEIL PATRICK R (Genera… | ≈0.04% | 61 470 | 2026-06-26 |
| GEARY RICHARD S (Officer… | ≈0.04% | 59 657 | 2025-11-06 |
| BAROLDI JOSEPH (Officer) | — | — | 2026-06-26 |
| BENNETT C FRANK (Officer… | — | — | 2026-07-07 |
| HAYDEN MICHAEL REUBEN (D… | — | — | 2026-07-31 |
Sign in with Google